Home › Compare › MVRBF vs SBUX

MVRBF vs SBUX: Dividend Comparison 2026

MVRBF yields 243.90% · SBUX yields 2.84%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MVRBF wins by $394.45M in total portfolio value
10 years
MVRBF
MVRBF
● Live price
243.90%
Share price
$0.82
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$394.62M
Annual income
$218,439,906.42
Full MVRBF calculator →
SBUX
SBUX
● Live price
2.84%
Share price
$86.72
Annual div
$2.46
5Y div CAGR
48.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$167.0K
Annual income
$71,136.45
Full SBUX calculator →

Portfolio growth — MVRBF vs SBUX

📍 MVRBF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMVRBFSBUX
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MVRBF + SBUX cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
MVRBF pays
SBUX pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MVRBF
Annual income on $10K today (after 15% tax)
$20,731.71/yr
After 10yr DRIP, annual income (after tax)
$185,673,920.46/yr
SBUX
Annual income on $10K today (after 15% tax)
$241.12/yr
After 10yr DRIP, annual income (after tax)
$60,465.98/yr
At 15% tax rate, MVRBF beats the other by $185,613,454.47/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MVRBF + SBUX for your $10,000?

MVRBF: 50%SBUX: 50%
100% SBUX50/50100% MVRBF
Portfolio after 10yr
$197.39M
Annual income
$109,255,521.44/yr
Blended yield
55.35%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on SBUX right now

MVRBF
No analyst data
Altman Z
1.7
Piotroski
0/9
SBUX
Analyst Ratings
28
Buy
27
Hold
3
Sell
Consensus: Buy
Price Target
$104.00
+19.9% upside vs current
Range: $90.00 — $120.00
Altman Z
2.6
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MVRBF buys
0
SBUX buys
0
No recent congressional trades found for MVRBF or SBUX in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMVRBFSBUX
Forward yield243.90% ✓2.84%
Annual dividend / share$2.00$2.46 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%48.3% ✓
Portfolio after 10y$394.62M ✓$167.0K
Annual income after 10y$218,439,906.42 ✓$71,136.45
Total dividends collected$375.65M ✓$136.4K
Payment frequencyquarterlyquarterly
SectorStockConsumer Discretionary

Year-by-year: MVRBF vs SBUX ($10,000, DRIP)

YearMVRBF PortfolioMVRBF Income/yrSBUX PortfolioSBUX Income/yrGap
1← crossover$35,090$24,390.24$11,121$420.68+$24.0K → MVRBF
2$117,533$79,986.88$12,548$648.40+$105.0K → MVRBF
3$376,147$250,386.00$14,440$1,013.98+$361.7K → MVRBF
4$1,151,374$748,897.11$17,068$1,617.30+$1.13M → MVRBF
5$3,374,355$2,142,384.97$20,912$2,649.52+$3.35M → MVRBF
6$9,478,533$5,867,972.46$26,875$4,499.29+$9.45M → MVRBF
7$25,546,778$15,404,747.63$36,771$8,014.12+$25.51M → MVRBF
8$66,138,099$38,803,046.68$54,542$15,197.11+$66.08M → MVRBF
9$164,653,072$93,885,306.32$89,602$31,242.49+$164.56M → MVRBF
10$394,618,693$218,439,906.42$167,011$71,136.45+$394.45M → MVRBF

MVRBF vs SBUX: Complete Analysis 2026

MVRBF — Stock

Medivir AB (publ) researches, develops, and sells pharmaceuticals primarily for the treatment of oncology in Sweden and internationally. The company markets Xerclear for the treatment of labial herpes under the Zoviduo name. It also develops Remetinostat for treating MF cutaneous T-cell lymphoma, as well as basal cell carcinoma. In addition, the company develops MIV-818 for the treatment of liver cancer; MIV-711 to treat osteoarthritis; and Birinapant and IGM-8444 for the treatment of solid tumors. It has a research collaboration with the Drug Discovery and Development Platform at SciLifeLab for the discovery of antivirals for SARS CoV-2; and a licensing agreement with the Tango Therapeutics for a preclinical research program, as well as Ubiquigent Limited for the preclinical research program USP7. Medivir AB (publ) was incorporated in 1987 and is based in Huddinge, Sweden.

Full MVRBF Calculator →

SBUX — Consumer Discretionary

Starbucks Corporation, together with its subsidiaries, operates as a roaster, marketer, and retailer of specialty coffee worldwide. The company operates through three segments: North America, International, and Channel Development. Its stores offer coffee and tea beverages, roasted whole beans and ground coffees, single serve products, and ready-to-drink beverages; and various food products, such as pastries, breakfast sandwiches, and lunch items. The company also licenses its trademarks through licensed stores, and grocery and foodservice accounts. The company offers its products under the Starbucks, Teavana, Seattle's Best Coffee, Evolution Fresh, Ethos, Starbucks Reserve, and Princi brands. As of October 3, 2021, it operated 16,826 company-operated and licensed stores in North America; and 17,007 company-operated and licensed stores internationally. The company was founded in 1971 and is based in Seattle, Washington.

Full SBUX Calculator →
📬

Get this MVRBF vs SBUX comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MVRBF vs SCHDMVRBF vs JEPIMVRBF vs OMVRBF vs KOMVRBF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.